Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy

被引:44
|
作者
Ray, P [1 ]
Quantin, X [1 ]
Grenier, J [1 ]
Pujol, JL [1 ]
机构
[1] CHU Montpellier, Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier, France
来源
CANCER DETECTION AND PREVENTION | 1998年 / 22卷 / 04期
关键词
chemotherapy; CYFRA; 21-1; cytokeratins; lung cancer; neuron-specific enolase; survival; tissue polypeptide-specific antigen; tumor markers; tumor response;
D O I
10.1046/j.1525-1500.1998.CDOA43.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was (i) to determine predictive factors of a complete response to chemotherapy in small cell lung cancer (SCLC) and predictive factors of an objective response in non-small cell lung cancer (NSCLC) and (ii) to determine whether prognostic factors are different with regard to treatment response and survival. Ninety-nine patients with SCLC and two hundred and two patients with NSCLC received chemotherapy. The following variables were recorded prior to treatment: tumor, node, metastasis status, performance status, body weight loss, blood leukocyte count, serum sodium, serum albumin, lactate dehydrogenase (LDH), alkaline phosphatase, serum NSE, serum TPS, and serum CYFRA 21-1. Tumor response was analyzed at the 10th week. Analysis of survival were done using the landmark method. Hazard ratios of the significant prognostic variables of survival were calculated using the Cox's model. Odds ratios of the significant predicting factors of response were calculated by stepwise logistic regression. In SCLC, the significant determinants of poor survival were: lack of complete response (HR: 2.04), weight loss (HR: 1.76), high serum LDH level (HR: 1.64), and high serum TPS level (HR: 2.47). A high serum TPS level was the only factor among those studied able to predict lack of achievement of complete response (OR: 0.39). In NSCLC, significant determinants of poor survival were: no objective response (HR: 2.28), poor performance status (HR: 2.52), presence of metastases (HR: 1.51), and high serum CYFRA 21-1 level (HR: 1.84). On the other hand, a high serum TPS level (OR: 0.50), the presence of metastases (OR: 0.45), and a leukocyte blood count over 10,000/mu l (OR: 0.43) were independent determinants for a patient not to achieve an objective response. We concluded that the predictive factors of complete response in SCLC remain to be defined. On the other hand, in NSCLC three variables contribute to the prediction of an objective response. Finally, determinants of survival differ from predictive factors of response.
引用
收藏
页码:293 / 304
页数:12
相关论文
共 50 条
  • [21] Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy
    Elias A. Kotteas
    Ioannis Gkiozos
    Sofia Tsagkouli
    Antonios Bastas
    Ioannis Ntanos
    Muhammad W. Saif
    Konstantinos N. Syrigos
    Medical Oncology, 2013, 30
  • [22] Prognostic factors in small cell lung cancer
    Torun, Elif
    Fidan, Ali
    Caglayan, Benan
    Salepci, Taflan
    Mayadagli, Alpaslan
    Salepci, Banu
    TUBERKULOZ VE TORAK-TUBERCULOSIS AND THORAX, 2008, 56 (01): : 22 - 29
  • [23] Second-Line Chemotherapy of Advanced Colorectal Cancer: Predictive and Prognostic Factors
    Forgacz, Krzysztof
    Agrawal, Anil K.
    Sawicki, Tomasz
    Marek, Grzegorz W.
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 25 (04): : 725 - 732
  • [24] Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
    Miscoria, Manuela
    Tonetto, Fabrizio
    Deroma, Laura
    Machin, Piernicola
    Di Loreto, Carla
    Driol, Pamela
    Minisini, Alessandro Marco
    Russo, Stefania
    Andreetta, Claudia
    Mansutti, Mauro
    Damante, Giuseppe
    Fasola, Gianpiero
    Puglisi, Fabio
    ANTI-CANCER DRUGS, 2012, 23 (03) : 326 - 334
  • [25] Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer
    Sakurada, Takumi
    Kakiuchi, Soji
    Tajima, Soichiro
    Horinouchi, Yuya
    Okada, Naoto
    Nishisako, Hirotaka
    Nakamura, Toshimi
    Teraoka, Kazuhiko
    Kawazoe, Kazuyoshi
    Yanagawa, Hiroaki
    Nishioka, Yasuhiko
    Minakuchi, Kazuo
    Ishizawa, Keisuke
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 398 - 404
  • [26] Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection
    Damirov, Fuad
    Stoleriu, Mircea Gabriel
    Manapov, Farkhad
    Boedeker, Enole
    Dreher, Sascha
    Gerz, Sibylle
    Hehr, Thomas
    Sandner, Evelin
    Ott, German
    Hatz, Rudolf Alexander
    Preissler, Gerhard
    CANCERS, 2024, 16 (16)
  • [27] Prognostic value of tumor volume for patients with advanced lung cancer treated with chemotherapy
    Kuo, Chung-Feng Jeffrey
    Ke, Bo-Han
    Wu, Nain-Ying
    Kuo, Joseph
    Hsu, Hsian-He
    COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2017, 144 : 165 - 177
  • [28] Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer
    Ekstrom, Anders
    Brun, Eva
    Eberhard, Jakob
    Segerlantz, Mikael
    ACTA ONCOLOGICA, 2021, 60 (12) : 1580 - 1588
  • [29] ELEVATED SURVIVIN IS OF PROGNOSTIC SIGNIFICANCE FOR NON-RESPONSE TO CHEMOTHERAPY AND REDUCED SURVIVAL IN LUNG CANCER WITH MALIGNANT PLEURAL EFFUSIONS
    Hwang, K-E
    Jeong, E-T
    Kim, H-R
    RESPIROLOGY, 2011, 16 : 142 - 142
  • [30] Survival of kurdish patients with lung cancer and some related factors
    Bahari, Nahid
    Payandeh, Mehrdad
    Tarlan, Mitra
    Izadi, Neda
    CLINICAL CANCER INVESTIGATION JOURNAL, 2020, 9 (06): : 258 - 263